Alkermes plc (ALKS) Company Profile & Statistics

Alkermes plc
ALKS
(Nasdaq - US)
Closed
27.68
-0.23 (-0.82%)
in:usd•As of: Nov 21, 2024 15:59 UTC -5
Open
27.93
High
28.14
Low
27.48

About Alkermes plc

CEO

Richard F. Pops

Headquarters

1 burlington road,connaught house

dublin, l2 dublin 4, ireland

Auditor

PricewaterhouseCoopers LLP

Employees

2,100

Share Holders

100

Website

http://www.alkermes.com

Industry

pharmaceuticals major

Sector

health technology

Company Overview

Alkermes plc, formed by the merger of Waltham, MA-based Alkermes, Inc. and Elan Drug Technologies (EDT), is a fully integrated global biopharmaceutical company that utilizes proprietary technologies to research, develop and commercialize, both with partners and on its own pharmaceutical products in major therapeutic areas. Alkermes holds a diversified product portfolio and a promising pipeline of candidates targeting major central nervous system (CNS) disorders including schizophrenia, depression, addiction and multiple sclerosis. Alkermes derives revenues on net sales of its proprietary products: Vivitrol & Aristada, and manufacturing and/or royalty revenues on net sales of products commercialized by the company's partners. These include Risperdal Consta, Invega Sustenna/Xeplion, Invega Trinza/Trevicta, Ampyra/Fampyra and Bydureon. Interesting late-stage candidate in the company's pipeline include nemvaleukin alfa developed for treating advanced solid tumors. Its proprietary drugs are Vivitrol & Aristada.

Alkermes plc Statistics

Valuation Measures

Market Capitalization ²	4.48B
Enterprise Value	4.37B
Enterprise Value/EBITDA (ttm)	12.39
Price to Earnings Ratio (ttm)	14.94
Price to Book (mrq)	3.44
Price to Sales (ttm)	2.95
Price to Cash (ytd)	12.11

Profitability

Gross Margin (ttm)	83.15%
Operating Margin (ttm)	20.84%
Profit Margin (ttm)	21.93%
Return on Equity (ttm)	24.92%
Return on Invested Capital (ttm)	25.21%
Return on Assets (ttm)	14.55%

Income Statement

Revenue (ttm)	1.51B
Revenue Per Share (ttm)	9.30
Gross Profit (ttm)	1.25B
EBITDA (ttm)³	352.81M
Net Income Avi to Common (ttm)	333.35M
Diluted EPS (ttm)	1.95

Share Statistics

Beta (5Y Monthly)	0.47
52-Week Change	14.47%
S&P500 52-Week Change	30.55%
S&P500 Member	No
Stock Optionable	Yes
Total Shares Outstanding ¹	161.80M
Dividend Yield	0.00%
Float ⁴	153.89M
% Held by Insiders	4.89%
% Held by Institutions	95.21%

Balance Sheet

Total Cash (mrq)	908.86M
Total Cash Per Share (mrq)	5.62
Total Debt (mrq)	288.82M
Total Debt/Equity (mrq)	22.35%
Current Ratio (mrq)	3.45%
Quick Ratio (mrq)	3.03%
Book Value Per Share (mrq)	7.99

Cash Flow

Operating Cash Flow Per Share (ytd)	1.49
Free Cash Flow (ytd)	225.47M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. Stock price provided by Xignite. All numbers are rounded to the closest decimal.

¹ Total Shares outstanding is taken from the most recently filed quarterly or annual report.

² Market Cap is calculated using total shares outstanding and the most recent share price.

³ EBITDA is calculated using methodology that may differ from that used by a company in its reporting.

⁴ The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

Alkermes plc

Trade With A Regulated Broker